WhaleCreep

RA Capital Management, L.P. 13F holdings, Q4 2020

Hedge fundSEC filingsCompare with another fundHoldings as of 2020-12-31, filed 2021-02-16

RA Capital Management, L.P. disclosed 82 US equity positions worth $7.2bn in its Q4 2020 13F filing. Its largest position is ASND at 13.7% of the reported book, followed by TGTX and NVAX. Versus Q3 2020 it opened 23 new positions, added to 4, reduced 17 and exited 11.

$7.2bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
82
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
13.7%
Largest position
The largest single position as a share of the reported equity book.
50.8%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
24
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
73
Quarters on file since Q4 2007
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q3 2020: 23 new, 4 added, 17 reduced, 11 exited

50 of 82
ASND ASCENDIS PHARMA A/SHealthcare13.7%$978m5.87m−0.8%reduced
TGTX TG THERAPEUTICS INCHealthcare6.3%$452m8.69m−1.6%reduced
NVAX NOVAVAX INCHealthcare5.9%$422m3.79m+216%added
NKTX NKARTA INCHealthcare4.8%$345m5.61m0.0%held
FORMA THERAPEUTICS HLDGS INC no ticker–4.4%$315m9.01m0.0%held
ARVN ARVINAS INCHealthcare4.4%$312m3.67m0.0%held
CCXIEUR CHEMOCENTRYX INC–4.1%$296m4.78m−1.0%reduced
AVIR ATEA PHARMACEUTICALS INCHealthcare3.1%$224m5.37m–new
2662247D ITEOS THERAPEUTICS INC–2.1%$149m4.42m0.0%held
KNTEUSD KINNATE BIOPHARMA INC–2.0%$143m3.59m–new
AXSM AXSOME THERAPEUTICS INC.Healthcare1.9%$135m1.66m−19%reduced
KROS KEROS THERAPEUTICS INCHealthcare1.8%$132m1.88m0.0%held
PHAT PHATHOM PHARMACEUTICALS INCHealthcare1.8%$127m3.83m0.0%held
RYTM RHYTHM PHARMACEUTICALS INCHealthcare1.7%$124m4.18m−19%reduced
TVTX TRAVERE THERAPEUTICS INCHealthcare1.7%$124m4.56m–new
IMGNEUR IMMUNOGEN INC–1.7%$119m18.42m+162%added
RCKT ROCKET PHARMACEUTICALS INCHealthcare1.6%$117m2.14m–new
ETNBGBP 89BIO INC–1.6%$115m4.74m0.0%held
ZGNXEUR ZOGENIX INC–1.5%$107m5.35m−2.6%reduced
PMVP PMV PHARMACEUTICALS INCHealthcare1.5%$105m1.71m0.0%held
OLMA OLEMA PHARMACEUTICALS INCHealthcare1.4%$103m2.15m–new
ADVMCHF ADVERUM BIOTECHNOLOGIES INC–1.4%$103m9.50m+1.0%added
MGNX MACROGENICS INCHealthcare1.4%$100m4.38m0.0%held
PCVX VAXCYTE INCHealthcare1.4%$98.6m3.71m−30%reduced
1K0 IGM BIOSCIENCES INC–1.2%$86.8m982,7230.0%held
BDTX BLACK DIAMOND THERAPEUTICS IHealthcare1.2%$83.0m2.59m0.0%held
SPRY ARS PHARMACEUTICALS INCHealthcare1.1%$80.7m1.74m–new
TREUR TRILLIUM THERAPEUTICS INC–1.1%$77.8m5.29m−14%reduced
SLDB SOLID BIOSCIENCES INCHealthcare1.1%$75.6m9.98m+118%added
KALA PHARMACEUTICALS INC no ticker–1.0%$73.7m10.87m0.0%held
FPRX FIVE PRIME THERAPEUTICS INC–1.0%$72.9m4.29m–new
INBXUSD INHIBRX INC–1.0%$70.2m2.13m0.0%held
LEGN LEGEND BIOTECH CORPHealthcare0.9%$67.8m2.41m0.0%held
CRIS CURIS INCHealthcare0.9%$63.1m7.71m–new
WVE WAVE LIFE SCIENCES LTDHealthcare0.9%$61.2m7.78m0.0%held
CRDF CARDIFF ONCOLOGY INC–0.8%$59.2m3.29m0.0%held
DYN DYNE THERAPEUTICS INCHealthcare0.8%$58.9m2.81m0.0%held
CNST CONSTELLATION PHARMCETICLS I–0.7%$53.4m1.85m–new
PACB PACIFIC BIOSCIENCES CALIF INHealthcare0.7%$51.6m1.99m–new
GERN GERON CORPHealthcare0.7%$47.9m30.13m0.0%held
STRO SUTRO BIOPHARMA INCHealthcare0.6%$46.0m2.12m0.0%held
CCCC C4 THERAPEUTICS INCHealthcare0.6%$45.6m1.38m–new
AKOUOS INC no ticker–0.6%$45.2m2.28m0.0%held
RLAY RELAY THERAPEUTICS INCHealthcare0.6%$41.6m1.00m0.0%held
INOZYME PHARMA INC no ticker–0.6%$41.4m2.00m0.0%held
ORTXUSD ORCHARD THERAPEUTICS PLC–0.6%$41.2m12.32m0.0%held
ARDX ARDELYX INCHealthcare0.6%$39.9m6.16m−1.6%reduced
CERE1EUR CEREVEL THERAPEUTICS HLDNG I–0.5%$36.5m2.20m–new
ARQT ARCUTIS BIOTHERAPEUTICS INCHealthcare0.5%$32.8m1.17m0.0%held
LRMR LARIMAR THERAPEUTICS INCHealthcare0.5%$32.4m1.52m0.0%held

Exited since Q3 2020

11 rows
MCRB SERES THERAPEUTICS INC2.5%$134m
EIDXGBP EIDOS THERAPEUTICS INC2.0%$109m
RTRXEUR RETROPHIN INC1.6%$85.6m
RLMD RELMADA THERAPEUTICS INC0.5%$29.4m
PREVAIL THERAPEUTICS INC no ticker0.4%$19.5m
FS DEV CORP no ticker0.2%$11.2m
VSTM VERASTEM INC0.2%$9.8m
ARYA SCIENCES ACQUISTION CO no ticker0.1%$7.7m
GALERA THERAPEUTICS INC no ticker0.1%$7.5m
CLDX CELLDEX THERAPEUTICS INC NEW0.10%$5.2m
EPIEUR ESSA PHARMA INC0.06%$3.2m

Sector mix

  • Healthcare67.7%
  • Unclassified32.3%

Book over time

Every quarter on file (73)
QuarterPositionsEquity book
Q2 202684$11.5bn
Q1 202685$9.4bn
Q4 202571$9.8bn
Q3 202567$8.1bn
Q2 202563$5.9bn
Q1 202585$6.0bn
Q4 202489$7.5bn
Q3 202481$8.7bn
Q2 202478$7.6bn
Q1 202476$7.9bn
Q4 202362$6.4bn
Q3 202366$5.1bn
Q2 202354$5.3bn
Q1 202359$4.4bn
Q4 202270$4.9bn
Q3 202281$4.7bn
Q2 202288$3.8bn
Q1 202296$4.6bn
Q4 202197$5.7bn
Q3 202195$7.2bn
Q2 202192$6.2bn
Q1 202182$6.6bn
Q4 202082$7.2bn
Q3 202070$5.5bn
Q2 202057$5.1bn
Q1 202048$3.2bn
Q4 201934$3.3bn
Q3 201932$1.7bn
Q2 201925$1.9bn
Q1 201929$2.3bn
Q4 201825$1.7bn
Q3 201826$1.9bn
Q2 201827$1.5bn
Q1 201831$1.3bn
Q4 201727$1.2bn
Q3 201727$1.1bn
Q2 201722$871m
Q1 201724$815m
Q4 201627$706m
Q3 201630$969m
Q2 201632$722m
Q1 201642$782m
Q4 201537$1.0bn
Q3 201547$696m
Q2 201558$928m
Q1 201556$913m
Q4 201448$777m
Q3 201443$622m
Q2 201424$756m
Q1 201429$973m
Q4 201324$648m
Q3 201331$724m
Q2 201325$616m
Q1 201317$407m
Q4 201219$225m
Q3 201221$198m
Q2 201226$223m
Q1 201223$185m
Q4 201118$124m
Q3 201120$90.3m
Q2 201120$108m
Q1 201121$130m
Q4 201016$101m
Q3 201018$101m
Q1 201021$102m
Q4 200914$75.1m
Q2 200916$107m
Q1 200912$184m
Q4 20088$224m
Q3 200820$329m
Q2 200822$220m
Q1 200817$135m
Q4 200723$159m

Where RA Capital Management, L.P. was early

110 rows
VRTX VERTEX PHARMACEUTICALS INCQ1 20082 of 16012.5%12.5%7Exited by Q4 2014+370%
AMAG AMAG PHARMACEUTICALS INCQ2 20081 of 693.4%9.2%7Exited by Q3 2010+2.4%
GILD GILEAD SCIENCES INCQ4 20087 of 1810.7%15.8%6Exited by Q2 2020+192%
BSTC BIOSPECIFICS TECHNOLOGIES COQ1 20091 of 299.0%32.9%7Exited by Q3 2011–
ALXN ALEXION PHARMACEUTICALS INCQ2 20092 of 1476.6%9.6%5Exited by Q2 2011–
UTHR UNITED THERAPEUTICS CORP DELQ2 20092 of 1617.0%7.0%5Exited by Q2 2011+61%
ENZB ENZO BIOCHEM INCQ1 20101 of 400.6%3.9%7Exited by Q1 2014–
ACAD ACADIA PHARMACEUTICALS INCQ1 20111 of 1456.5%21.1%17Exited by Q3 2015+2485%
NVAX NOVAVAX INCQ4 20111 of 1171.0%14.4%24Exited by Q2 2022+192%
SGMOQ SANGAMO THERAPEUTICS INCQ4 20111 of 852.0%13.6%22Exited by Q4 2017+428%
BCRX BIOCRYST PHARMACEUTICALS INCQ1 20121 of 1218.0%11.1%28Held at last filing, Q2 2026+107%
VSTM VERASTEM INCQ1 20121 of 1003.6%3.6%6Exited by Q4 2020−89%
IMMU IMMUNOMEDICS INCQ1 201311 of 1110.6%4.8%6Exited by Q1 2019+492%
ENTA ENANTA PHARMACEUTICALS INCQ2 20131 of 921.3%8.8%8Exited by Q1 2025−68%
INSM INSMED INCQ2 20131 of 1804.7%6.4%9Exited by Q2 2025+538%
OMER OMEROS CORPQ2 20131 of 662.4%2.4%4Exited by Q3 2015+257%
PRTA PROTHENA CORP PLCQ2 20131 of 1011.0%6.7%4Exited by Q2 2014+197%
TXMD THERAPEUTICSMD INCQ2 20131 of 655.5%9.4%13Exited by Q3 2021−61%
PTCT PTC THERAPEUTICS INCQ3 20131 of 1270.9%2.6%7Exited by Q3 2015+124%
TGTX TG THERAPEUTICS INCQ3 20131 of 1140.4%6.8%30Exited by Q1 2022+277%
T8S TESARO INCQ4 20131 of 833.1%3.1%4Exited by Q3 2015+108%
XNCR XENCOR INCQ4 20131 of 1023.8%3.8%13Held at last filing, Q2 2026+76%
MGNX MACROGENICS INCQ4 201310 of 1040.8%2.6%16Held at last filing, Q2 2026−83%
SCYX SCYNEXIS INCQ2 20141 of 470.9%1.1%4Exited by Q2 2015+3.5%
AKBA AKEBIA THERAPEUTICS INCQ2 20142 of 1032.2%2.2%5Exited by Q3 2017−48%
TENX TENAX THERAPEUTICS INCQ3 20143 of 561.5%1.5%10Exited by Q1 2017−50%
CHRS COHERUS BIOSCIENCES INCQ4 20141 of 1053.3%5.2%6Exited by Q2 2016+30%
AUPH AURINIA PHARMACEUTICALS INCQ4 20142 of 1001.2%1.2%3Exited by Q3 2015−17%
ASND ASCENDIS PHARMA A/SQ1 20151 of 1371.9%29.9%46Held at last filing, Q2 2026+1437%
DVAX DYNAVAX TECHNOLOGIES CORPQ1 20151 of 1166.4%6.4%4Exited by Q1 2020−75%
2655787D BLUEPRINT MEDICINES CORPQ2 20151 of 1472.5%2.7%4Exited by Q2 2016−32%
COLL COLLEGIUM PHARMACEUTICAL INCQ2 20151 of 963.0%4.9%4Exited by Q2 2016+1.7%
MCRB SERES THERAPEUTICS INCQ2 20151 of 751.1%2.5%5Exited by Q3 2021−43%
ARDX ARDELYX INCQ2 20152 of 1143.0%4.4%15Exited by Q3 2021−53%
AIMT AIMMUNE THERAPEUTICS INCQ3 20151 of 742.9%2.9%6Exited by Q1 2017−19%
NTRA NATERA INCQ3 20151 of 1671.2%1.3%6Exited by Q3 2022+227%
ACRS ACLARIS THERAPEUTICS INCQ4 20151 of 1146.8%6.8%15Held at last filing, Q2 2026−80%
WVE WAVE LIFE SCIENCES LTDQ4 20151 of 12311.2%26.3%43Held at last filing, Q2 2026−64%
ONC BEIGENE LTDQ1 20164 of 1040.6%1.1%5Exited by Q2 2017+25%
NKTR NEKTAR THERAPEUTICSQ1 20165 of 1455.6%6.5%4Exited by Q4 2023−96%
PTGX PROTAGONIST THERAPEUTICS INCQ3 20162 of 1361.6%2.1%3Exited by Q2 2017−39%
4XC1 KALVISTA PHARMACEUTICALS INCQ4 20161 of 910.6%1.8%15Exited by Q2 2022+108%
KDMN KADMON HLDGS INCQ3 20173 of 762.0%2.0%2Exited by Q1 2018+8.1%
SCPH SCPHARMACEUTICALS INCQ4 20171 of 642.9%2.9%19Exited by Q1 2023−41%
SPRO SPERO THERAPEUTICS INCQ4 20171 of 441.2%1.2%3Exited by Q3 2018+25%
IFRX INFLARX NVQ4 20172 of 575.0%5.0%8Exited by Q4 2025−94%
SG7 SAGE THERAPEUTICS INCQ4 201714 of 1326.3%6.3%5Exited by Q2 2019−3.4%
SLDB SOLID BIOSCIENCES INCQ1 20181 of 951.5%6.8%34Held at last filing, Q2 2026−91%
IOVA IOVANCE BIOTHERAPEUTICS INCQ1 20186 of 1300.9%1.4%5Exited by Q2 2019−44%
RYTM RHYTHM PHARMACEUTICALS INCQ2 20183 of 1143.1%7.3%33Held at last filing, Q2 2026+255%

Concentration and tenure

18.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
70.5%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters